Chronic fatigue syndrome: aspects of diagnosis and treatment from modern positions


DOI: https://dx.doi.org/10.18565/therapy.2020.1.129-135

Stryuk R.I., Berns S.A., Yun V.L.

A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia
The article discusses the aspects of prevalence, pathogenetic mechanisms of development, clinical manifestations, diagnosis and modern approaches to the treatment of chronic fatigue syndrome, the frequency of which gets up to 80% in reproductive age females. The necessity for a comprehensive individualized approach to treatment is emphasized and practicability of using meldonium (Mildronate®), a drug that belongs to the cytoprotectors group, antihypoxants, which provide protection and energy supply to various cells of the body under conditions of ischemia and increased load, is substantiated.
Keywords: reproductive age females, chronic fatigue syndrome, meldonium
Read entire article

Literature


  1. Beard G. American Nervousness. Its Causes and Consequences. G.P Putnam, New York. 1881; 7–9.

  2. Комаров С.Г. Синдром хронической усталости (распространенность и организация здравоохранения). Автореф. дис. … канд. мед. наук. Москва, 2008; 67 с.

  3. Buchwald D., Pearlman T., Umali J., Schmaling K., Katon W. Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals. The American Journal of Medicine. 1996; 101(4): 364–70.

  4. Steele L., Dobbins J.G., Fukuda K. et al. The epidemiology of chronic fatigue in San Francisco. The American Journal of Medicine. 1998; 105(3): 83–90.

  5. Smith M.E.B., Nelson H.D., Haney E. et al. AHRQ evidence report on diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome can be found at AHRQ Evidence Report 2015.

  6. Friedberg F., Bateman L., Bested A.C. et al. International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFS/ME). Chronic fatigue syndrome/myalgic encephalomyelitis: a primer for clinical practitioners. IACFS/ME 2012.

  7. Clayton E.W. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. JAMA. 2015 Mar 17; 313(11): 1101. doi: 10.1001/jama.2015.1346.

  8. Togo F., Natelson B.H., Cherniack N.S., FitzGibbons J., Garcon C., Rapoport D.M. Sleep structure and sleepiness in chronic fatigue syndrome with or without coexisting fibromyalgia. Arthritis Res Ther. 2008; 10(3): R56. doi: 10.1186/ar2425.

  9. Maes M., Twisk F.N., Kubera M., Ringel K. Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin. J Affect Disord. 2012 Feb; 136(3): 933–39. doi: 10.1016/j.jad.2011.09.004.

  10. Kennedy G., Spence V., Underwood C., Belch J.J. Increased neutrophil apoptosis in chronic fatigue syndrome. J Clin Pathol. 2004 Aug; 57(8): 891–93.

  11. Morris G., Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis. 2014 Mar; 29(1): 19–36.doi: 10.1007/s11011-013-9435-x.

  12. Парахонский А.П. Синдром хронической усталости и иммунной дисфункции. Международный журнал экспериментального образования. 2010; 7: 39–40.

  13. Jason L.A. et al. CFS prevalence and risk factors over time. J Health Psychol. 2011 Apr; 16(3): 445–56.doi: 10.1177/1359105310383603.

  14. Hotopf M. et al. Why do children have chronic abdominal pain, and what happens to them when they grow up? Population based cohort study. BMJ. 1998; 7139(316): 1196–1200.

  15. Регистрационное удостоверение препарата Мельдоний, капсулы, 500 мг, Акционерное Общество «Гриндекс», Латвия, ЛС-001115 от 21.08.2017 [Electronic resource]. Государственный реестр лекарственных средств. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c9ee2b7f-6066-43ea-810d-6d01f53d07bf&t= (accessed: 30.07.2019).

  16. Максимова М.Ю., Федорова Т.Н., Шарыпова Т.Н. Применение Милдроната в лечении больных с нарушениями мозгового кровообращения. Фарматека. 2013; 9: 84–94. [Maksimova M.Yu., Fedorova T.N., Sharypova T.N. Use of Mildronate in treatment of patients with brain circulation dysfunction. Pharmateca. 2013; 9: 84–94 (In Russ.)].

  17. Максимова М.Ю., Кистенев Б.А., Домашенко М.А. с соавт. Клиническая эффективность и антиоксидантная активность милдроната при ишемическом инсульте. Российский кардиологический журнал. 2009; 4(78): 54–62. [Maksimova M.Yu., Kistenev B.A., Domashenko M.A. et al. Clinical efficacy and antioxidant activity of Mildronate in ischemic stroke. Rossiyskiy cardiologicheskiy zhurnal. 2009; 4(78): 54–62 (In Russ.)].

  18. Дамулин И.В., Коберская Н.Н., Антоненко Л.М. Влияние милдроната на когнитивные нарушения при дисциркуляторной энцефалопатии: клинико-электрофизиологическое исследование. Неврологический журнал. 2006; 1: 1–6. [Damulin I.V., Koberskaya N.N. Antonenko L.M. Influence of Mildronate on cognitive impairments in discirculatory encephalopathy: clinical and electrophysiological investigation. Nevrologicheskiy zhurnal. 2006; 1: 1–6.(In Russ.)].

  19. Дамулин И.В., Антоненко Л.М., Коберская Н.Н. Влияние милдроната на двигательные расстройства при дисциркуляторной энцефалопатии. РМЖ. 2006; 1: 28–32. [Damulin I.V., Antonenko L.M., Koberskaya N.N. The effect of Mildronate on motor disorders in discirculatory encephalopathy. Rossiyskiy medicinskiy zhurnal. 2006; 1: 28–32(In Russ.)].

  20. Михин В.П., Хлебодаров Ф.Е., Васильева Д.А., Стребкова Е.Д. Эффективность милдроната у больных гипертонической болезнью с очень высоким сердечно-сосудистым риском на фоне терапии эналаприлом. Медицинский алфавит. 2018; 1(4): 7–11. [Mikhin V.P., Khlebodarov F.E., Vasilyeva D.A., Strebkova E.D. Efficacy of mildronate in patients with hypertensive disease with very high cardiovascular risk during enalapril therapy. Medicinskiy alphavit. 2018; 1(4): 7–11 (In Russ.)].

  21. Groppa S. et al. The complex treatment of Mildronate among patients with acute cerebral circulation disorders, and the dynamics of the changes in higher cognitive functions. Curierul medical. 2012; 4(328): 61–63.

  22. Grosu A. et al. Acute myocardial infarction: association of Mildronate with basic therapy. Curierul medical. 2012; 1(325): 6–9.

  23. Zhu Y. et al. Efficacy and safety of mildronate for acute ischemic stroke: a randomized, double-blind, active-controlled phase II multicenter trial. Clin Drug Investig. 2013;. 33(10): 755–60. doi: 10.1007/s40261-013-0121-x.

  24. Гимоян Л.Г., Силванян Г.Г. Применение милдроната в лечении когнитивных нарушений при сосудистой деменции. РМЖ. 2017; 21(25): 1518–1524. [Gimoyan L.G., Silvanyan G.G. The use of Mildronate in the treatment of cognitive impairments in vascular dementia. Rossiyskiy medicinskiy zhurnal. 2017; 21(25): 1518–1524 (In Russ.)].

  25. Шавловская О.А. Терапия астении и связанных с ней состояний. Медицинский совет. 2015; 17: 55–61. [Shavlovskaya O.A. Therapy of asthenia and associated impairments. Medicinskiy sovet. 2015; 17: 55–61 (In Russ.)].

  26. Усова Н.Н., Галиновская Н.В., Латышева В.Я. Коррекция синдрома вегетативной дистонии у детей и подростков с использованием препарата Милдронат® (mildronate). Рецепт. 2007; 2(52): 91–94. Usova N.N., Galinovskaya N.V., Latysheva V.Ya. Correction of vegetative-vascular dystonia in children and adolescents by use of preparation Mildronate. Retsept. 2007; 2(52): 91–94. (in Russ.)].

  27. Циркин В.И., Нуреев И.Т., Злоказова М.В., Трухина С.И. Влияние милдроната на состояние центральной нервной системы у студентов с признаками синдрома дефицита внимания с гиперреактивностью. Вестник Нижегородского университета им. Н.И. Лобачевского. 2010; 6: 105–112. [Tsirkin V.I., Nureev I.T., Zlokazova M.V., Trukhina S.I. The influence of Mildronate on the condition of central nervous system of students with attention deficit hyperactivity disorder (ADHD) syndrome. Vestnik Nizhegorodskogo Universiteta imeni N.I. Lobachevskogo. 2010; 6: 105–112 (in Russ,)].

  28. Логунова Л.В. Новые аспекты в использовании милдроната для профилактики и коррекции нарушений адаптационных процессов. Вестник РУДН. Серия: Медицина. 2010; 2: 17–24. [Logunova L.V. New views of Mildronate use for the prevention and correction of impairment of adaptive processes. Vestnik RUDN. Medicina. 2010; 2: 17 – 24. (In Russ.)].


About the Autors

Raisa I. Stryuk, MD, professor, honored doctor of the Russian Federation, head of the Department of internal medicine of the Faculty of dentistry of A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (903) 565-73-88. E-mail: rstryuk@list.ru
Svetlana A. Berns, MD, professor of the Department of internal medicine, faculty of dentistry of A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (916) 929-08-92. E-mail: svberns@yandex.ru
Victoria L. Yun, Ph.D., assistant of the Department of internal medicine, faculty of dentistry of A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (916) 929-08-92. E-mail: yun.v.l@inbox.ru


Similar Articles

Back to Content

Бионика Медиа